.png){kind=icon}
返回
M
Mazen Noureddin
cedars sinai medical center
72H指数
546论文数
2.0W被引数
收录论文 247
发表时间
.png){kind=icon}
The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial胰高血糖素和GLP-1受体双重激动剂DD01用于代谢功能障碍相关脂肪性肝病和脂肪性肝炎（DD01-DN-02）：一项随机、双盲、多中心、安慰剂对照、2期试验的12周结果.png)
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏
Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH TrialResmetirom对体重减轻和/或糖尿病患者代谢功能障碍相关非酒精性脂肪性肝炎的影响：一项MAESTRO-NASH试验的二次分析（患者同时接受胰高血糖素样肽-1受体激动剂和其他糖尿病疗法）
OAAI
OAAI分享收藏Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial代谢功能障碍相关脂肪性肝炎（HARMONY）中，每周一次efruxifermin相较于安慰剂的疗效与安全性：一项多中心、随机、双盲、安慰剂对照、2b期试验的96周结果.png)
lancet
lancetIF0
PREAI
分享收藏